-
EP2435421
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP2435421
| EP2435421 - ANTIVIRAL COMPOUNDS COMPOSED OF THREE ALIGNED ARYL MOIETIES TO TREAT DISEASES SUCH AS HEPATITIS C [Right-click to bookmark this link] | Status | The application is deemed to be withdrawn Status updated on 06.03.2015 Database last updated on 15.06.2024 | Most recent event Tooltip | 06.03.2015 | Application deemed to be withdrawn | published on 08.04.2015 [2015/15] | Applicant(s) | For all designated states Merck Sharp & Dohme Corp. 126 East Lincoln Avenue Rahway, NJ 07065-0907 / US | [N/P] |
| Former [2012/33] | For all designated states Merck Sharp & Dohme Corp. 126 East Lincoln Avenue Rahway NJ 07065-0907 / US | ||
| Former [2012/14] | For all designated states Schering Corporation 2000 Galloping Hill Road Kenilworth, NJ 07033 / US | Inventor(s) | 01 /
CHEN, Kevin, X. 2000 Galloping Hill Road Kenilworth, New Jersey 07033 / US | 02 /
ANILKUMAR, Gopinadhan, N. 2000 Galloping Hill Road Kenilworth, NewJersey 07033 / US | 03 /
ZENG, Qingbei 2000 Galloping Hill Road Kenilworth, New Jersey 07033 / US | 04 /
ROSENBLUM, Stuart, B. 2000 Galloping Hill Road Kenilworth, New Jersey 07033 / US | 05 /
KOZLOWSKI, Joseph, A. 2000 Galloping Hill Road Kenilworth, New Jersey 07033 / US | 06 /
NJOROGE, F., George 2000 Galloping Hill Road Kenilworth, New Jersey 07033 / US | [2012/14] | Representative(s) | Horgan, James Michael Frederic, et al Merck Sharp & Dohme Corp. 120 Moorgate London, EC2M 6UR / GB | [N/P] |
| Former [2012/14] | Horgan, James Michael Frederic, et al Merck & Co., Inc. European Patent Department Merck Sharpe & Dohme Limited Hertford Road Hoddesdon Hertfordshire EN11 9BU / GB | Application number, filing date | 10721905.7 | 28.05.2010 | WO2010US36520 | Priority number, date | US20090182375P | 29.05.2009 Original published format: US 182375 P | US20090243728P | 18.09.2009 Original published format: US 243728 P | [2012/14] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2010138790 | Date: | 02.12.2010 | Language: | EN | [2010/48] | Type: | A1 Application with search report | No.: | EP2435421 | Date: | 04.04.2012 | Language: | EN | The application published by WIPO in one of the EPO official languages on 02.12.2010 takes the place of the publication of the European patent application. | [2012/14] | Search report(s) | International search report - published on: | EP | 02.12.2010 | Classification | IPC: | C07D401/14, C07D403/14, C07D409/14, C07D417/14, A61K31/4184, A61K31/12 | [2012/14] | CPC: |
C07D401/14 (EP,US);
A61P1/16 (EP);
A61P31/14 (EP);
C07D403/14 (EP,US);
C07D409/14 (EP,US);
C07D417/14 (EP,US)
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR [2012/14] | Title | German: | AUS DREI IN EINER REIHE AUSGERICHTETEN ARYLEINHEITEN ZUSAMMENGESETZTE ANTIVIRALE VERBINDUNGEN ZUR BEHANDLUNG VON KRANKHEITEN WIE HEPATITIS C | [2012/14] | English: | ANTIVIRAL COMPOUNDS COMPOSED OF THREE ALIGNED ARYL MOIETIES TO TREAT DISEASES SUCH AS HEPATITIS C | [2012/14] | French: | COMPOSÉS ANTIVIRAUX CONSTITUÉS DE TROIS FRACTIONS D'ARYLE ALIGNÉES POUR TRAITER DES MALADIES TELLES QUE L'HÉPATITE C | [2012/14] | Entry into regional phase | 29.12.2011 | National basic fee paid | 29.12.2011 | Designation fee(s) paid | 29.12.2011 | Examination fee paid | Examination procedure | 29.12.2011 | Examination requested [2012/14] | 16.08.2012 | Amendment by applicant (claims and/or description) | 15.07.2013 | Despatch of a communication from the examining division (Time limit: M06) | 24.02.2014 | Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time [2015/15] | 17.04.2014 | Reply to a communication from the examining division | 14.10.2014 | Cancellation of oral proceeding that was planned for 06.11.2014 | 24.10.2014 | Despatch of communication that the application is refused, reason: substantive examination {1} | 04.11.2014 | Application deemed to be withdrawn, date of legal effect [2015/15] | 06.11.2014 | Date of oral proceedings (cancelled) | Divisional application(s) | The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is 15.07.2013 | Request for further processing for: | The application is deemed to be withdrawn due to failure to reply to the examination report | 17.04.2014 | Request for further processing filed | 17.04.2014 | Full payment received (date of receipt of payment) Request granted | 20.06.2014 | Decision despatched | 16.08.2012 | Request for further processing filed | 16.08.2012 | Full payment received (date of receipt of payment) Request granted | 13.09.2012 | Decision despatched | Fees paid | Renewal fee | 21.03.2012 | Renewal fee patent year 03 | 26.03.2013 | Renewal fee patent year 04 | 26.03.2014 | Renewal fee patent year 05 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [A]WO2008021927 (BRISTOL MYERS SQUIBB CO [US], et al) [A] 1-16 * Compounds of:;; claim 20 * * Pharmaceutical compositions:;; claims 35-40 * * Use in therapy of HCV infections:;; claims 41-46 *; | [A]WO2008070447 (GENELABS TECH INC [US], et al) [A] 1-16 * Compounds of:; page 25 - page 36; table 1 * * Pharmaceutical compositions:;; claim 28 * * use in therapy of HCV infections:;; claims 30-33 *; | [IP]WO2010017401 (BRISTOL MYERS SQUIBB CO [US], et al) [IP] 1-16 * General teaching of Markush formula (I) of:;; claim 1 * * Pharmaceutical compositions:;; claims 17-22 * * Use in HCV infections:;; claims 23-28 * * examples M46, V2-V5,V7-V10, JG2-JG4 * * All examples featuring an oxazol-2,5-diyl linker; page 153 - page 178; examples J6b-J28 *; | [A] - UWE KOCH AND FRANK NARJES, "Recent Progress in the Development of Inhibitors of the Hepatitis C Virus RNA-Dependent RNA Polymerase", CURRENT TOPICS IN MEDICINAL CHEMISTRY, BENTHAM SCIENCE PUBLISHERS LTD, NETHERLANDS, (20070101), vol. 7, ISSN 1568-0266, pages 1302 - 1329, XP007914635 [A] 1-16 * the whole document * DOI: http://dx.doi.org/10.2174/156802607781212211 | Examination | WO2010065681 | WO2010091413 | WO2010099527 | WO2010132601 | WO2011009084 | WO2011050146 | - LIMA L M ET AL, "Bioisosterism: A Useful Strategy for Molecular Modification and Drug Design", vol. 12, no. 1, ISSN 0929-8673, (20050101), pages 23 - 49, CURRENT MEDICINAL CHEMISTRY, BENTHAM SCIENCE PUBLISHERS, NL, URL: http://www.bentham.org/cmc/samples/cmc12-1/0002C.pdf, XP002523330 | by applicant | - TANJI ET AL., J. VIROL., (1995), vol. 69, pages 3980 - 3986 | - HUANG, Y ET AL., VIROLOGY, (2007), vol. 364, pages 1 - 9 | - M. CAIRA ET AL., J. PHARMACEUTICAL SCI., (2004), vol. 93, no. 3, pages 601 - 611 | - E. C. VAN TONDER ET AL., AAP.5 PHARMSCITECHOURS., (2004), vol. 5, no. 1 | - A. L. BINGHAM ET AL., CHENL COINMUN., (2001), pages 603 - 604 | - S. BERGE ET AL., JOURNAL OF PHANNACEUTICAL SCIENCES, (1977), vol. 66, no. 1, pages 1 - 19 | - CHOSHI ET AL., J. ORG. CHEM., (1997), vol. 62, pages 2535 - 2543 | - SCOTT ET AL., J. AM. CHEM. SOC., (1984), vol. 106, page 4630 | - ANGEW CHEM. INT. ED. ENGL, (2001), vol. 40, page 4544 | - ZHOU ET AL., J. AM. CHERN. SOC., (2003), vol. 127, pages 12537 - 12530 | - KUMADA, PURE APPL. CHEM., (1980), vol. 52, page 669 | - FU ET AL., ANGEW. CHEM., (2002), vol. 114, page 4363 | - ORGANIC LETTERS; ENGLISH, (2009), vol. II, no. 20, pages 4664 - 4667 | - MALCOLM ET AL., ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, (2006), vol. 50, pages 1013 - 1020 | - K. DEL CARMEN ET AL., ANNALS OF HEPATOLOGY, (2004), vol. 3, page 54 | - PIETSCHMANN, T.; BARTENSCHLAGER, R., CURRENT OPINION IN DRUG DISCOVERY RESEARCH, (2001), vol. 4, pages 657 - 664 | - HOLLAND, PATHOLOGY, (1998), vol. 30, no. 2, pages 192 - 195 | - SIMMONDS ET AL., J GEN VIROL, (1993), vol. 74, pages 2391 - 2399 | - LAMBALLERIE ET AL., J GEN VIROL, (1997), vol. 78, pages 45 - 51 | - SIMMONDS ET AL., J GEN VIROL, (1994), vol. 75, pages 1053 - 1061 | - NI ET AL., CURRENT OPINION IN DRUG DISCOVERY AND DEVELOPMENT, (2004), vol. 7, no. 4, page 446 | - TAN ET AL., NATURE REVIEWS, (2002), vol. 1, page 867 | - BEAULIEU ET AL., CURRENT OPINION IN INVESTIGATIONAL DRUGS, (2004), vol. 5, page 838 | - LANDRO ET AL., BIOCHEMISTRY, (1997), vol. 36, no. 31, pages 9340 - 9348 | - INGALLINCLLA ET AL., BIOCHEMISTRY, (1998), vol. 37, no. 25, pages 8906 - 8914 | - LLINàS-BRUNET ET AL., BIOORG MED CHEM LETT, (1998), vol. 8, no. 13, pages 1713 - 1718 | - MARTIN ET AL., BIOCHEMISTRY, (1998), vol. 37, no. 33, pages 11459 - 11468 | - DIMASI ET AL., J VIROL, (1997), vol. 71, no. 10, pages 7461 - 7469 | - MARTIN ET AL., PROTEIN ENG, (1997), vol. 10, no. 5, pages 607 - 614 | - ELZOUKI ET AL., J HEPAT, (1997), vol. 27, no. 1, pages 42 - 48 | - BIOWORLD TODAY, (19981110), vol. 9, no. 217, page 4 |